Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

Phase 3UnknownNCT03193502

Sherief Abd-Elsalam40 enrolled

Overview

-Rivaroxaban is factor Xa inhibitor

PVT is a common complication of liver cirrhosis

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

rivaroxaban

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Acute PVT Exclusion Criteria: * Malignant PVT * Bleeding disorders

Tropical medicine dept.-Tanta university hospital

Cairo, Egypt

RECRUITING

Number of patients with recanalized portal vein

recanalization of portal vein

Time frame: 6 months

Sherief Abd-Elsalam, consultant

CONTACT

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.